medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2008, Number 3

<< Back Next >>

Rev Mex Oftalmol 2008; 82 (3)

Estudio de la eficacia y tolerancia de una nueva formulación de latanoprost al 0.005% vs. travoprost en glaucoma primario de ángulo abierto

Baiza-Durán LM, Casab-Rueda H

Language: Spanish
References: 24
Page: 166-172
PDF size: 78.86 Kb.


ABSTRACT

Objectives: To compare the efficacy and tolerance of a new latanoprost formulation vs. those of travoprost in patients with primary open-angle glaucoma or ocular hypertension.
Materials and methods: A prospective, randomized and double blind study was carried out. Patients with primary openangle glaucoma or ocular hypertension were enrolled. As an efficacy primary parameter, the intraocular pressure was evaluated. Conjunctival hyperemia and tearing were evaluated as a safety and tolerance parameters, respectively. The patients were included randomly in two therapy groups, one receiving latanoprost and the other one travoprost. Intraocular pressure daytime curves were performed.
Results: 30 patients were included: 21 females, 9 males (average age of 59.3 ±8 years old). Both medicaments diminished the intraocular pressure in a similar way without statistically significant differences found (p›0.05), even in the pressure daytime curve. The travoprost group showed a higher percentage of patients with conjunctival hyperemia, burning sensation and tearing with a statistically significant difference in favor of latanoprost (p‹0.05) regarding both parameters.
Conclusions: The new formula of latanoprost 0.005% shows a hypotensive efficacy comparable to travoprost and with a safety and tolerance profile significantly higher than travoprost.


REFERENCES

  1. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol 1992; 113:447-452.

  2. Alward WL. Medical management of glaucoma. N Engl J Med 1998; 339:1298-307.

  3. Kass MA, Heuer DK, Higginbotham EJ y cols. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.

  4. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E and the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121:48-56.

  5. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002; 109:1955-1956.

  6. Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha. Curr Eye Res 1981; 1:205-209.

  7. Woodward DF, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophtalmol 1997; 41(supl 2):S15-S21.

  8. Lee PY, Shao H, Xu LA, Qu CK. The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects. Invest Ophtalmol Vis Sci 1988; 29:1474-1477.

  9. Stjernschantz JW. From PGF (2alpha)-isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci 2001; 42:1134-1145.

  10. Ravinet E, Mermoud A, Brignoli R. Four years later: a clinical update on latanoprost. Eur J Ophthalmol 2003; 13:162-175.

  11. Sjöquist B, Basu S, Byding P, Bergh K, Stjernschantz J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos 1998; 26:745-754.

  12. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47:S6-S12.

  13. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100:1297-1304.

  14. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins, I: drug solubilization and stabilization. J Pharm Sci 1996; 85:1017-1025.

  15. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001; 225:15-30.

  16. Loftsson T, Stefansson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 2002; 80:144-150.

  17. Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA and the Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophtalmol 2001; 132: 860-868.

  18. Konstas AGP, Mantziris DA, Stewart WC, Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115:182-5.

  19. Konstas AGP, Nakos E,Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of Once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002; 133:753-757.

  20. Konstas AGP, Papanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of comercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110:1357-60.

  21. Gonzalez JR, Baiza-Duran L, Quintana-Hau J, Tornero-Montaño R y cols. Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation. J Clin Pharmacol 2007; 47:121-126.

  22. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: A 12-Week, randomized, masked evaluator multicenter study. Am J Ophthalmol 2003; 135:688-703.

  23. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124:544-7.

  24. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002; 47( Supl 1):S185-202.




2020     |     www.medigraphic.com